Literature DB >> 3919001

Primary structure of the reactive site of human C1-inhibitor.

G S Salvesen, J J Catanese, L F Kress, J Travis.   

Abstract

Human C1-inhibitor (C1-Inh) forms an equimolar complex with complement proteinase C1s that is resistant to dissociation by sodium dodecyl sulfate. The formation of this stable complex results in the cleavage of a peptide bond near the carboxyl terminus of the inhibitor and, whereas the bulk of C1-Inh remains covalently bound to the light chain of C1s, the postcomplex inhibitor peptide can be isolated under denaturing conditions. We have sequenced the amino-terminal region of this peptide and deduced that it represents the carboxyl-terminal side of the reactive site of C1-Inh. Limited proteolysis of C1-Inh by Crotalus atrox protease results in an active derivative lacking an amino-terminal peptide of 36 residues. Further proteolysis of this derivative with Pseudomonas aeruginosa elastase inactivates the inhibitor and a peptide is released. The amino-terminal sequence of this peptide overlaps with that of the postcomplex peptide and indicates that the residue imparting primary specificity to the inhibitor is arginine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919001

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Cold-dependent activation of complement: recognition, assessment, and mechanism.

Authors:  K P Mathews; R A Mentyka; S L Chambers; T E Hugli; J H Herschbach; B L Zuraw
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

3.  Inactivation of various proteinase inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens.

Authors:  A Molla; T Akaike; H Maeda
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

4.  Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.

Authors:  M H Prandini; A Reboul; M G Colomb
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

5.  Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.

Authors:  J H Nuijens; C C Huijbregts; G M van Mierlo; C E Hack
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

6.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

Review 7.  Aspects of C1-inhibitor biochemistry and pathophysiology.

Authors:  T K Nilsson
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

8.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.

Authors:  J Alsenz; J D Lambris; K Bork; M Loos
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

10.  Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation.

Authors:  K S Aulak; P A Pemberton; F S Rosen; R W Carrell; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.